Trevi Therapeutics, Inc. (TRVI): Price and Financial Metrics


Trevi Therapeutics, Inc. (TRVI): $1.32

0.01 (+0.76%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

TRVI Stock Price Chart Interactive Chart >

Price chart for TRVI

TRVI Price/Volume Stats

Current price $1.32 52-week high $4.10
Prev. close $1.31 52-week low $1.28
Day low $1.29 Volume 42,100
Day high $1.38 Avg. volume 75,586
50-day MA $1.75 Dividend yield N/A
200-day MA $2.37 Market Cap 28.51M

Trevi Therapeutics, Inc. (TRVI) Company Bio


Trevi Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of treatment for neurologically mediated conditions. It focuses on the formulation of nalbuphine ER, which use to treat chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease. The company was founded by Thomas R. Sciascia and Jennifer L. Good on March 17, 2011 and is headquartered in New Haven, CT.


TRVI Latest News Stream


Event/Time News Detail
Loading, please wait...

TRVI Latest Social Stream


Loading social stream, please wait...

View Full TRVI Social Stream

Latest TRVI News From Around the Web

Below are the latest news stories about Trevi Therapeutics Inc that investors may wish to consider to help them evaluate TRVI as an investment opportunity.

Trevi Therapeutics Announces Second Quarter 2021 Financial Results and Business Update

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of an investigational therapy Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced financial results for the quarter ended June 30, 2021, as well as business updates.

Yahoo | August 12, 2021

Trevi Therapeutics Announces Additions to the Senior Leadership Team

NEW HAVEN, Conn., Aug. 9, 2021 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (nalbuphine ER) to treat serious neurologically mediated conditions,

PR Newswire | August 9, 2021

Trevi Therapeutics to Report Q2 2021 Financial Results on August 12

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of an investigational therapy Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced that management will host a conference call and live audio webcast on Thursday, August 12 at 4:30 p.m. ET, to provide a corporate update and review the Company's financial results for the quarter ended June 30, 2021.

Yahoo | August 5, 2021

Trevi Therapeutics to Present at 2021 BIO Digital Conference

NEW HAVEN, Conn., June 9, 2021 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (nalbuphine ER) to treat serious neurologically mediated conditions,

PR Newswire | June 9, 2021

BMO Capital Thinks Trevi Therapeutics Stock is Going to Recover

In a report released today, Gary Nachman from BMO Capital assigned a Buy rating to Trevi Therapeutics (TRVI), with a price target of The post BMO Capital Thinks Trevi Therapeutics Stock is Going to Recover appeared first on Smarter Analyst .

Smarter Analyst | May 14, 2021

Read More 'TRVI' Stories Here

TRVI Price Returns

1-mo -22.81%
3-mo -39.73%
6-mo -51.29%
1-year -65.17%
3-year N/A
5-year N/A
YTD -45.45%
2020 -35.47%
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.904 seconds.